癲癇共患注意缺陷多動障礙發病機制的研究進展_Journal of Epilepsy

Authors：

奚曉雋 ^1,2 ,  湯繼宏 ¹

1. ;
2. ;

Corresponding?author：

湯繼宏, Email: tjhzsh@126.com

Keywords：

癲癇; 注意缺陷多動障礙; 共患病; 發病機制

DOI：

10.7507/2096-0247.20200055

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

大量高質量臨床研究顯示，雖然癲癇和注意缺陷多動障礙（Attention-deficit hyperactivity disorder，ADHD）為獨立疾病，但二者可能存在共同的發病機制，影像學的不斷發展及大腦網絡功能測定技術的興起進一步支持了該假設，快點燃及匹魯卡品誘導的癲癇動物模型為研究二者共病機制提供了基礎，去甲腎上腺素能通路的分子機制研究為探索治療新靶點提供了方向。文章對近年來關于癲癇共患 ADHD 發病機制的研究作一綜述，以期為相關疾病的臨床診治提供一定參考。

Citation： 奚曉雋, 湯繼宏. 癲癇共患注意缺陷多動障礙發病機制的研究進展. Journal of Epilepsy, 2020, 6(4): 341-344. doi: 10.7507/2096-0247.20200055 Copy

1.	Kaufmann R, Goldberg-Stern H, Shuper A. Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. J Child Neurol, 2009, 24(6): 727-733.
2.	Zhao Q, Wang M, Kang H, et al. Behavior problems in children with epilepsy and attention-deficit hyperactivity disorder in Central China. Epilepsy Behav, 2018, 89(79-83).
3.	Chou I C, Chang Y T, Chin Z N, et al. Correlation between epilepsy and attention deficit hyperactivity disorder: a population-based cohort study. PLoS One, 2013, 8(3): e57926.
4.	Bechtel N, Weber P. Attention problems in children with epilepsy. How is the long-term outcome? Eur J Paediatr Neurol, 2015, 19(3): 383-385.
5.	Ross EE, Stoyell SM, Kramer MA, et al. The natural history of seizures and neuropsychiatric symptoms in childhood epilepsy with centrotemporal spikes (CECTS). Epilepsy Behav, 2019: 106437.
6.	Ashjazadeh N, Sahraeian A, Sabzgolin I, et al. Attention-deficit hyperactivity disorder in adults with epilepsy. Epilepsy Behav, 2019, 101(Pt A): 106543.
7.	Ettinger AB, Ottman R, Lipton RB, et al. Attention-deficit/hyperactivity disorder symptoms in adults with self-reported epilepsy: Results from a national epidemiologic survey of epilepsy. Epilepsia, 2015, 56(2): 218-224.
8.	Bertelsen EN, Larsen JT, Petersen L, et al. Childhood epilepsy, febrile seizures, and subsequent risk of ADHD. Pediatrics, 2016, 138(2): e20154654.
9.	Mula M. Epilepsy and psychiatric comorbidities: drug selection. Curr Treat Options Neurol, 2017, 19(12): 44.
10.	Jason EA, Tomson T, Carlsson S, et al. Neurodevelopmental comorbidities and seizure control 24 months after a first unprovoked seizure in children. Epilepsy Res, 2018, 143: 33-40.
11.	Rheims S, Herbillon V, Villeneuve N, et al. ADHD in childhood epilepsy: clinical determinants of severity and of the response to methylphenidate. Epilepsia, 2016, 57(7): 1069-1077.
12.	Caplan R. ADHD in pediatric epilepsy: fact or fiction? Epilepsy Curr, 2017, 17(2): 93-95.
13.	Sherman EM, Slick DJ, Connolly MB, et al. ADHD, neurological correlates and health-related quality of life in severe pediatric epilepsy. Epilepsia, 2007, 48(6): 1083-1091.
14.	Hesdorffer DC, Ludvigsson P, Olafsson E, et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry, 2004, 61(7): 731-736.
15.	Wiggs KK, Chang Z, Quinn PD, et al. Attention-deficit/hyperactivity disorder medication and seizures. Neurology, 2018, 90(13): e1104-1110.
16.	Brikell I, Ghirardi L, D'Onofrio BM, et al. Familial liability to epilepsy and attention-deficit/hyperactivity disorder: A Nationwide cohort study. Biol Psychiatry, 2018, 83(2): 173-180.
17.	Park J, Choi HW, Yum MS, et al. Relationship between aggravation of seizures and methylphenidate treatment in subjects with attention-deficit/Hyperactivity disorder and epilepsy. J Child Adolesc Psychopharmacol, 2018, 28(8): 537-546.
18.	Brikell I, Chen Q, Kuja-Halkola R, et al. Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy. Epilepsia, 2019, 60(2): 284-293.
19.	Adams J, Alipio-Jocson V, Inoyama K, et al. Methylphenidate, cognition, and epilepsy: A double-blind, placebo-controlled, single-dose study. Neurology, 2017, 88(5): 470-476.
20.	Auvin S, Wirrell E, Donald KA, et al. Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE pediatric commission. Epilepsia, 2018, 59(10): 1867-1880.
21.	Fosi T, Lax-Pericall MT, Scott RC, et al. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. Epilepsia, 2013, 54(12): 2071-2081.
22.	Radziuk AL, Kieling RR, Santos K, et al. Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies. Epilepsy Behav, 2015, 46: 215-220.
23.	Santos K, Palmini A, Radziuk AL, et al. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. Dev Med Child Neurol, 2013, 55(7): 654-660.
24.	中國抗癲癇協會共患病專業委員會等. 兒童癲癇共患注意缺陷多動障礙診斷治療的中國專家共識. 癲癇雜志, 2018, 4(04): 281-289.
25.	Saute R, Dabbs K, Jones JE, et al. Brain morphology in children with epilepsy and ADHD. PLoS One, 2014, 9(4): e95269.
26.	Dabbs K, Jones JE, Jackson DC, et al. Patterns of cortical thickness and the Child Behavior Checklist in childhood epilepsy. Epilepsy Behav, 2013, 29(1): 198-204.
27.	Albajara Saenz A, Villemonteix T, Massat I. Structural and functional neuroimaging in attention-deficit/hyperactivity disorder. Dev Med Child Neurol, 2019, 61(4): 399-405.
28.	Kavros PM, Clarke T, Strug LJ, et al. Attention impairment in rolandic epilepsy: systematic review. Epilepsia, 2008, 49(9): 1570-1580.
29.	Downs J, Giust J, Dunn DW. Considerations for ADHD in the child with epilepsy and the child with migraine. Expert Rev Neurother, 2017, 17(9): 861-869.
30.	Holtmann M, Becker K, Kentner-Figura B, et al. Increased frequency of rolandic spikes in ADHD children. Epilepsia, 2003, 44(9): 1241-1244.
31.	Ma K, Yu J, Shao W, et al. Functional overlaps exist in neurological and psychiatric disorders: a proof from brain network analysis. Neuroscience, 2020, 425: 39-48.
32.	Sharma P, Dedeurwaerdere S, Vandenberg MA, et al. Neuroanatomical differences in FAST and SLOW rat strains with differential vulnerability to kindling and behavioral comorbidities. Epilepsy Behav, 2016, 65: 42-48.
33.	McIntyre DC, Gilby KL. Genetically seizure-prone or seizure-resistant phenotypes and their associated behavioral comorbidities. Epilepsia, 2007, 48(Suppl 9): 30-32.
34.	Pineda E, Jentsch JD, Shin D, et al. Behavioral impairments in rats with chronic epilepsy suggest comorbidity between epilepsy and attention deficit/hyperactivity disorder. Epilepsy Behav, 2014, 31: 267-275.
35.	Anderson GM, Dover MA, Yang BP, et al. Adrenomedullary function during cognitive testing in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 2000, 39(5): 635-643.
36.	Del Campo N, Chamberlain SR, Sahakian BJ, et al. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry, 2011, 69(12): e145-157.
37.	Winstanley CA. The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders. Br J Pharmacol, 2011, 164(4): 1301-1321.
38.	Medel-Matus JS, Shin D, Sankar R, et al. Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy. Exp Neurol, 2017, 289: 64-72.
39.	Kumar U, Medel-Matus JS, Redwine HM, et al. Effects of selective serotonin and norepinephrine reuptake inhibitors on depressive- and impulsive-like behaviors and on monoamine transmission in experimental temporal lobe epilepsy. Epilepsia, 2016, 57(3): 506-515.
40.	Helmstaedter C, Aldenkamp AP, Baker GA, et al. Disentangling the relationship between epilepsy and its behavioral comorbidities - the need for prospective studies in new-onset epilepsies. Epilepsy Behav, 2014, 31: 43-47.

1. Kaufmann R, Goldberg-Stern H, Shuper A. Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. J Child Neurol, 2009, 24(6): 727-733.
2. Zhao Q, Wang M, Kang H, et al. Behavior problems in children with epilepsy and attention-deficit hyperactivity disorder in Central China. Epilepsy Behav, 2018, 89(79-83).
3. Chou I C, Chang Y T, Chin Z N, et al. Correlation between epilepsy and attention deficit hyperactivity disorder: a population-based cohort study. PLoS One, 2013, 8(3): e57926.
4. Bechtel N, Weber P. Attention problems in children with epilepsy. How is the long-term outcome? Eur J Paediatr Neurol, 2015, 19(3): 383-385.
5. Ross EE, Stoyell SM, Kramer MA, et al. The natural history of seizures and neuropsychiatric symptoms in childhood epilepsy with centrotemporal spikes (CECTS). Epilepsy Behav, 2019: 106437.
6. Ashjazadeh N, Sahraeian A, Sabzgolin I, et al. Attention-deficit hyperactivity disorder in adults with epilepsy. Epilepsy Behav, 2019, 101(Pt A): 106543.
7. Ettinger AB, Ottman R, Lipton RB, et al. Attention-deficit/hyperactivity disorder symptoms in adults with self-reported epilepsy: Results from a national epidemiologic survey of epilepsy. Epilepsia, 2015, 56(2): 218-224.
8. Bertelsen EN, Larsen JT, Petersen L, et al. Childhood epilepsy, febrile seizures, and subsequent risk of ADHD. Pediatrics, 2016, 138(2): e20154654.
9. Mula M. Epilepsy and psychiatric comorbidities: drug selection. Curr Treat Options Neurol, 2017, 19(12): 44.
10. Jason EA, Tomson T, Carlsson S, et al. Neurodevelopmental comorbidities and seizure control 24 months after a first unprovoked seizure in children. Epilepsy Res, 2018, 143: 33-40.
11. Rheims S, Herbillon V, Villeneuve N, et al. ADHD in childhood epilepsy: clinical determinants of severity and of the response to methylphenidate. Epilepsia, 2016, 57(7): 1069-1077.
12. Caplan R. ADHD in pediatric epilepsy: fact or fiction? Epilepsy Curr, 2017, 17(2): 93-95.
13. Sherman EM, Slick DJ, Connolly MB, et al. ADHD, neurological correlates and health-related quality of life in severe pediatric epilepsy. Epilepsia, 2007, 48(6): 1083-1091.
14. Hesdorffer DC, Ludvigsson P, Olafsson E, et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry, 2004, 61(7): 731-736.
15. Wiggs KK, Chang Z, Quinn PD, et al. Attention-deficit/hyperactivity disorder medication and seizures. Neurology, 2018, 90(13): e1104-1110.
16. Brikell I, Ghirardi L, D'Onofrio BM, et al. Familial liability to epilepsy and attention-deficit/hyperactivity disorder: A Nationwide cohort study. Biol Psychiatry, 2018, 83(2): 173-180.
17. Park J, Choi HW, Yum MS, et al. Relationship between aggravation of seizures and methylphenidate treatment in subjects with attention-deficit/Hyperactivity disorder and epilepsy. J Child Adolesc Psychopharmacol, 2018, 28(8): 537-546.
18. Brikell I, Chen Q, Kuja-Halkola R, et al. Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy. Epilepsia, 2019, 60(2): 284-293.
19. Adams J, Alipio-Jocson V, Inoyama K, et al. Methylphenidate, cognition, and epilepsy: A double-blind, placebo-controlled, single-dose study. Neurology, 2017, 88(5): 470-476.
20. Auvin S, Wirrell E, Donald KA, et al. Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE pediatric commission. Epilepsia, 2018, 59(10): 1867-1880.
21. Fosi T, Lax-Pericall MT, Scott RC, et al. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. Epilepsia, 2013, 54(12): 2071-2081.
22. Radziuk AL, Kieling RR, Santos K, et al. Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies. Epilepsy Behav, 2015, 46: 215-220.
23. Santos K, Palmini A, Radziuk AL, et al. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. Dev Med Child Neurol, 2013, 55(7): 654-660.
24. 中國抗癲癇協會共患病專業委員會等. 兒童癲癇共患注意缺陷多動障礙診斷治療的中國專家共識. 癲癇雜志, 2018, 4(04): 281-289.
25. Saute R, Dabbs K, Jones JE, et al. Brain morphology in children with epilepsy and ADHD. PLoS One, 2014, 9(4): e95269.
26. Dabbs K, Jones JE, Jackson DC, et al. Patterns of cortical thickness and the Child Behavior Checklist in childhood epilepsy. Epilepsy Behav, 2013, 29(1): 198-204.
27. Albajara Saenz A, Villemonteix T, Massat I. Structural and functional neuroimaging in attention-deficit/hyperactivity disorder. Dev Med Child Neurol, 2019, 61(4): 399-405.
28. Kavros PM, Clarke T, Strug LJ, et al. Attention impairment in rolandic epilepsy: systematic review. Epilepsia, 2008, 49(9): 1570-1580.
29. Downs J, Giust J, Dunn DW. Considerations for ADHD in the child with epilepsy and the child with migraine. Expert Rev Neurother, 2017, 17(9): 861-869.
30. Holtmann M, Becker K, Kentner-Figura B, et al. Increased frequency of rolandic spikes in ADHD children. Epilepsia, 2003, 44(9): 1241-1244.
31. Ma K, Yu J, Shao W, et al. Functional overlaps exist in neurological and psychiatric disorders: a proof from brain network analysis. Neuroscience, 2020, 425: 39-48.
32. Sharma P, Dedeurwaerdere S, Vandenberg MA, et al. Neuroanatomical differences in FAST and SLOW rat strains with differential vulnerability to kindling and behavioral comorbidities. Epilepsy Behav, 2016, 65: 42-48.
33. McIntyre DC, Gilby KL. Genetically seizure-prone or seizure-resistant phenotypes and their associated behavioral comorbidities. Epilepsia, 2007, 48(Suppl 9): 30-32.
34. Pineda E, Jentsch JD, Shin D, et al. Behavioral impairments in rats with chronic epilepsy suggest comorbidity between epilepsy and attention deficit/hyperactivity disorder. Epilepsy Behav, 2014, 31: 267-275.
35. Anderson GM, Dover MA, Yang BP, et al. Adrenomedullary function during cognitive testing in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 2000, 39(5): 635-643.
36. Del Campo N, Chamberlain SR, Sahakian BJ, et al. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry, 2011, 69(12): e145-157.
37. Winstanley CA. The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders. Br J Pharmacol, 2011, 164(4): 1301-1321.
38. Medel-Matus JS, Shin D, Sankar R, et al. Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy. Exp Neurol, 2017, 289: 64-72.
39. Kumar U, Medel-Matus JS, Redwine HM, et al. Effects of selective serotonin and norepinephrine reuptake inhibitors on depressive- and impulsive-like behaviors and on monoamine transmission in experimental temporal lobe epilepsy. Epilepsia, 2016, 57(3): 506-515.
40. Helmstaedter C, Aldenkamp AP, Baker GA, et al. Disentangling the relationship between epilepsy and its behavioral comorbidities - the need for prospective studies in new-onset epilepsies. Epilepsy Behav, 2014, 31: 43-47.

Previous Article
癲癇對睡眠影響的研究
Next Article
腦炎后癲癇診斷與治療進展

Journal of Epilepsy

癲癇共患注意缺陷多動障礙發病機制的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content